The US Food and Drug Administration’s second meeting to ask an advisory committee about oral phenylephrine’s efficacy as a nasal decongestant won’t end with the ingredient’s critics and supporters agreeing.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?